{"protocolSection": {"identificationModule": {"nctId": "NCT01277523", "orgStudyIdInfo": {"id": "205.456"}, "secondaryIdInfos": [{"id": "2010-021778-13", "type": "EUDRACT_NUMBER", "domain": "EudraCT"}], "organization": {"fullName": "Boehringer Ingelheim", "class": "INDUSTRY"}, "briefTitle": "Efficacy and Safety of 2 Doses of Tiotropium Respimat Compared to Placebo in Adolescents With Severe Persistent Asthma", "officialTitle": "A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution Delivered Via Respimat\u00ae Inhaler (2.5 mcg and 5 mcg Once Daily) Over 12 Weeks as add-on Controller Therapy on Top of Usual Care in Adolescents (12 to 17 Years Old) With Severe Persistent Asthma"}, "statusModule": {"statusVerifiedDate": "2014-10", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2011-01"}, "primaryCompletionDateStruct": {"date": "2013-10", "type": "ACTUAL"}, "completionDateStruct": {"date": "2013-10", "type": "ACTUAL"}, "studyFirstSubmitDate": "2011-01-13", "studyFirstSubmitQcDate": "2011-01-13", "studyFirstPostDateStruct": {"date": "2011-01-17", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2014-10-14", "resultsFirstSubmitQcDate": "2014-10-14", "resultsFirstPostDateStruct": {"date": "2014-10-20", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2014-10-14", "lastUpdatePostDateStruct": {"date": "2014-10-20", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Boehringer Ingelheim", "class": "INDUSTRY"}, "collaborators": [{"name": "Pfizer", "class": "INDUSTRY"}]}, "descriptionModule": {"briefSummary": "The overall purpose of the trial is to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat\u00ae inhaler (2.5 mcg and 5 mcg once daily) over 12 weeks, compared to placebo, as add-on controller therapy on top of usual care in adolescents (12 to 17 years old) with severe persistent asthma.\n\nThe primary objective of the trial is to demonstrate superiority of tiotropium (5 mcg and possibly 2.5 mcg once daily in the evening) over placebo with regard to the primary pulmonary function endpoint after 12 weeks of treatment.\n\nSecondary objectives are to evaluate efficacy of tiotropium with regard to other endpoints, and to evaluate the safety of tiotropium, compared to placebo, as add-on controller therapy on top of usual care in this patient population."}, "conditionsModule": {"conditions": ["Asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE"}}, "enrollmentInfo": {"count": 392, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "A", "type": "EXPERIMENTAL", "interventionNames": ["Drug: tiotropium low dose"]}, {"label": "B", "type": "EXPERIMENTAL", "interventionNames": ["Drug: tiotropium high dose"]}, {"label": "C", "type": "PLACEBO_COMPARATOR", "interventionNames": ["Drug: placebo"]}], "interventions": [{"type": "DRUG", "name": "tiotropium high dose", "description": "2 actuations once daily", "armGroupLabels": ["B"]}, {"type": "DRUG", "name": "placebo", "description": "2 actuations once daily", "armGroupLabels": ["C"]}, {"type": "DRUG", "name": "tiotropium low dose", "description": "2 actuations once daily", "armGroupLabels": ["A"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "FEV1 peak0-3 Change From Baseline", "description": "Change from baseline in peak forced expiratory volume in 1 second within the first 3 hours post dosing (FEV1 peak0-3) measured at week 12.\n\nMeasured values presented are actually adjusted means.", "timeFrame": "Baseline and 12 weeks"}], "secondaryOutcomes": [{"measure": "Trough FEV1 Change From Baseline", "description": "Change from baseline in Trough (pre-dose) Forced expiratory volume in 1 second (FEV1) measured at week 12.\n\nMeasured values presented are actually adjusted means.", "timeFrame": "Baseline and 12 weeks"}, {"measure": "FVC peak0-3 Change From Baseline", "description": "Change from baseline in Maximum forced vital capacity (FVC) measured within the first 3 hours after administration of trial medication (FVC peak0-3h) after 12 weeks of treatment.\n\nThe measured values presented are actually adjusted means.", "timeFrame": "Baseline and 12 weeks"}, {"measure": "FEV1 AUC (0-3h) Change From Baseline", "description": "Change from baseline of area under the curve (AUC) from 0 to 3 hours for FEV1 (FEV1 AUC 0-3h) after 12 weeks of treatment. The AUC was calculated by using the trapezoidal rule divided by the observation time (3h).\n\nMeasured values presented are actually adjusted means.", "timeFrame": "Baseline and 10 mins before drug administration and 30 mins, 1 hour (h), 2h, 3h after drug administration at 12 weeks"}, {"measure": "FVC AUC (0-3h) Change From Baseline", "description": "Change from baseline of area under the curve (AUC) from 0 to 3 hours for FVC (Forced vital capacity) (FVC AUC0-3h) after 12 weeks of treatment. The AUC was calculated by using the trapezoidal rule divided by the observation time (3h).\n\nMeasured values presented are actually adjusted means.", "timeFrame": "Baseline and 10 mins before drug administration and 30 mins, 1 hour (h), 2h, 3h after drug administration at 12 weeks"}, {"measure": "Control of Asthma as Assessed by ACQ6 Score.", "description": "Change from baseline in Asthma Control Questionnaire (ACQ) 6 score measured at week 12\n\nThe ACQ is a scale containing 7 questions, each question has a 7 point scale which ranges from 0 to 6. A score of 0 corresponds to no impairment and a score of 6 corresponds to maximum impairment. ACQ6 score is calculated as the mean of the responses to the first 6 questions of the ACQ6.\n\nThe measured values presented are actually adjusted means.", "timeFrame": "Baseline and 12 weeks"}, {"measure": "ACQ6 Score Responders", "description": "Responder rates based on the ACQ6 score after 12 weeks of treatment. Analysis was performed using the following categories and definitions: responder (change from trial baseline \\<= -0.5), no change (-0.5 \\< change from trial baseline \\<0.5) and worsening (change from trial baseline \\>= 0.5).\n\nThe ACQ is a scale containing 7 questions, each question has a 7- point scale which ranges from 0 to 6; a score of 0 corresponds to no impairment and a score of 6 corresponds to maximum impairment. ACQ6 is calculated as the mean of the responses to the first 6 questions of the ACQ6.\n\nNo statistical testing was performed on ACQ6 responders.", "timeFrame": "12 weeks"}, {"measure": "Control of Asthma as Assessed by ACQ Total Score", "description": "Change from baseline in Asthma Control Questionnaire (ACQ) total score measured at week 12.\n\nThe ACQ is a scale containing 7 questions. Each question has a 7 point scale which ranges from 0 to 6. A score of 0 corresponds to no impairment and a score of 6 corresponds to maximum impairment. ACQ total score is calculated as the mean of the responses to all 7 questions.\n\nThe measured values presented are actually adjusted means.", "timeFrame": "Baseline and 12 weeks"}, {"measure": "ACQ Total Score Responders", "description": "Responder rates based on the ACQ total score after 12 weeks of treatment. Analysis was performed using the following categories and definitions: responder (change from trial baseline \u2264-0.5), no change (-0.5 \\<change from trial baseline \\<0.5) and worsening (change from trial baseline \u22650.5) No statistical testing was performed for ACQ total score responders.\n\nThe ACQ is a scale containing 7 questions, each question has a 7-point scale which ranges from 0 to 6; a score of 0 corresponds to no impairment and a score of 6 corresponds to maximum impairment.", "timeFrame": "12 weeks"}, {"measure": "Use of PRN Rescue Medication During the Day", "description": "Change from baseline in the number of puffs of rescue medication (salbutamol/albuterol) used during the day (24 hour period) based on the weekly mean at week 12.\n\nThe measured values presented are actually adjusted means.", "timeFrame": "Baseline and 12 weeks"}, {"measure": "Use of PRN Rescue Medication During the Daytime", "description": "Change from baseline in the number of puffs of rescue medication (salbutamol/albuterol) used during the daytime based on the weekly mean at week 12.\n\nMeasured values presented are actually adjusted means.", "timeFrame": "Baseline and 12 weeks"}, {"measure": "Use of PRN Rescue Medication During the Night-time", "description": "Change from baseline in the number of puffs of rescue medication (salbutamol/albuterol) used during the night-time based on the weekly mean at week 12.\n\nMeasured values presented are actually adjusted means", "timeFrame": "Baseline and 12 weeks"}, {"measure": "Time to First Severe Asthma Exacerbation During the 12-week Treatment Period.", "description": "Time in days to first severe asthma exacerbation during the 12 week treatment period. The median time to first severe asthma exacerbation was not calculable, so the number of patients who experienced a severe asthma exacerbation are presented for the measured values.\n\nA severe asthma exacerbation was defined as a subgroup of all asthma exacerbations that required an initiation of treatment with systemic corticosteroids for at least 3 days or, in case of ongoing and pre-existing systemic corticosteroid therapy, requiring at least doubling of previous daily doses of systemic corticosteroids for at least 3 days.", "timeFrame": "12 weeks"}, {"measure": "Analysis of Time to First Asthma Exacerbation During the 12 Week Treatment Period.", "description": "Time in days to first asthma exacerbation during the 12 week treatment period. The median time to first asthma exacerbation was not calculable, so the number of patients who experienced an asthma exacerbation are presented for the measured values.", "timeFrame": "12 weeks"}, {"measure": "Clinically Relevant Abnormalities for Physical Examination, ECG, Vital Signs and Laboratory Tests", "description": "Clinically relevant abnormalities for physical examination, ECG, vital signs and laboratory tests. New abnormal findings or worsening of baseline conditions were reported as adverse events.", "timeFrame": "From first drug administration until 30 days after last drug intake, up to 142 days"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion criteria:\n\n1. All patients and their parent(s) (or legally accepted representative) must sign and date respectively an informed assent and an informed consent consistent with International Conference on Harmonisation - Harmonised Tripartite Guideline for Good Clinical Practice (ICH-GCP) guidelines and local legislation prior to the patient's participation in the trial. A separate informed consent/assent is required for pharmacogenomic sampling.\n2. Male or female patients between 12 and 17 years of age (at date of informed consent/assent).\n3. All patients must have at least a 3-month history of asthma at the time of enrolment into the trial.\n4. All patients must have been on maintenance treatment with an inhaled corticosteroid either at stable high dose in combination with another controller medication, OR at stable medium dose in combination with two other controller medications, for at least 4 weeks before Visit 1.\n5. All patients must be symptomatic at Visit 1 (screening) and prior to randomisation at Visit 2 as defined by an Asthma Control Questionnaire (ACQ) mean score of = 1.5.\n6. All patients must have a pre-bronchodilator Forced Expiratory Volume in 1 second (FEV1) = 60% and = 90% of predicted normal at Visit 1.\n7. Variation of absolute FEV1 values of Visit 1 (pre-bronchodilator, considered as 100%) as compared to Visit 2 (pre-dose) must be within \u00b1 30%.\n8. All patients must confirm the diagnosis of asthma by bronchodilator reversibility at Visit 1, resulting in an increase in FEV1 of = 12% and = 200 mL 15 to 30 minutes after 400 \u00b5g salbutamol (albuterol). If patients in the lower age range (e.g. 12 to 14 year old patients) exhibit a very small total lung volume, positive reversibility testing might be based solely on the relative (=12%) post-bronchodilator response.\n9. All patients must be never-smokers or ex-smokers who stopped smoking at least one year prior to enrolment.\n10. Patients must be able to use the Respimat\u00ae inhaler correctly.\n11. Patients must be able to perform all trial related procedures including technically acceptable spirometric manoeuvres according to American Thoracic Society/ European Respiratory Society (ATS/ERS) standards and use of the electronic diary/peak flow meter (diary compliance of at least 80% is required).\n\nExclusion criteria:\n\n1. Significant disease other than asthma.\n2. Abnormal haematology or blood chemistry.\n3. History of heart disease, and/or hospitalised for cardiac syncope or failure.\n4. Any unstable or life-threatening or requiring intervention or cardiac arrhythmia.\n5. Malignancy for which the patient has undergone resection, radiation therapy or chemotherapy.\n6. Active tuberculosis.\n7. Alcohol or drug abuse.\n8. Thoracotomy with pulmonary resection.\n9. Pulmonary rehabilitation program.\n10. Hypersensitivity to anticholinergic drugs, or any components of the study medication delivery system.\n11. Pregnant or nursing adolescent female patients.\n12. Female patients of child-bearing potential not using a highly effective method of birth control.\n13. Investigational drug within four weeks or six half lives prior to Visit 1.\n14. Long-acting anticholinergics within four weeks prior to Visit 1.\n15. Systemic corticosteroids at a high dose or at a not stable low dose within four weeks prior to Visit 1.\n16. Leukotriene modifiers if not stabilised for at least four weeks prior to Visit 1.\n17. Long-acting theophylline preparations if not stabilised for at least two weeks prior to Visit 1.\n18. Anti Immunoglobulin E (Anti-IgE) treatment if not stabilised for at least six months prior to Visit 1.\n19. Cromones if not stabilised within four weeks prior to Visit 1.\n20. Oral beta-blocker medication within four weeks prior to Visit 1.\n21. Systemic oral or i.v. or s.c. beta-adrenergics within four weeks prior to Visit 1.\n22. Other non-approved and according to international guidelines not recommended experimental drugs for routine asthma therapy within four weeks prior to Visit 1.\n23. Any acute asthma exacerbation or respiratory tract infection in the four weeks prior to Visit 1and/or in the four weeks prior to Visit 2. In case of an asthma deterioration occurring in the four weeks prior to Visit 1 and/or in the four weeks prior to Visit 2, the visit must be postponed.\n24. Randomised in this trial or currently participating in another trial.\n25. Narrow-angle glaucoma, or any other disease where anticholinergic treatment is contraindicated.\n26. Moderate to severe renal impairment.\n27. Patients requiring 10 or more puffs of rescue medication per day on more than 2 consecutive days in the four weeks prior to Visit 1 and/or in the four weeks prior to Visit 2. In case of an asthma deterioration occurring in the four weeks prior to Visit 1 and/or in the four weeks prior to Visit 2, the visit must be postponed.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "12 Years", "maximumAge": "17 Years", "stdAges": ["CHILD"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Boehringer Ingelheim", "affiliation": "Boehringer Ingelheim", "role": "STUDY_CHAIR"}], "locations": [{"facility": "205.456.01004 Boehringer Ingelheim Investigational Site", "city": "Stockton", "state": "California", "country": "United States", "geoPoint": {"lat": 37.9577, "lon": -121.29078}}, {"facility": "205.456.01008 Boehringer Ingelheim Investigational Site", "city": "Normal", "state": "Illinois", "country": "United States", "geoPoint": {"lat": 40.5142, "lon": -88.99063}}, {"facility": "205.456.01003 Boehringer Ingelheim Investigational Site", "city": "Baltimore", "state": "Maryland", "country": "United States", "geoPoint": {"lat": 39.29038, "lon": -76.61219}}, {"facility": "205.456.01007 Boehringer Ingelheim Investigational Site", "city": "Columbia", "state": "Missouri", "country": "United States", "geoPoint": {"lat": 38.95171, "lon": -92.33407}}, {"facility": "205.456.01002 Boehringer Ingelheim Investigational Site", "city": "Bellevue", "state": "Nebraska", "country": "United States", "geoPoint": {"lat": 41.13667, "lon": -95.89084}}, {"facility": "205.456.01001 Boehringer Ingelheim Investigational Site", "city": "Rockville Centre", "state": "New York", "country": "United States", "geoPoint": {"lat": 40.65871, "lon": -73.64124}}, {"facility": "205.456.01005 Boehringer Ingelheim Investigational Site", "city": "Cincinnati", "state": "Ohio", "country": "United States", "geoPoint": {"lat": 39.12713, "lon": -84.51435}}, {"facility": "205.456.01006 Boehringer Ingelheim Investigational Site", "city": "Summerville", "state": "South Carolina", "country": "United States", "geoPoint": {"lat": 33.0185, "lon": -80.17565}}, {"facility": "205.456.54002 Boehringer Ingelheim Investigational Site", "city": "Capital Federal", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "205.456.54006 Boehringer Ingelheim Investigational Site", "city": "Capital Federal", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "205.456.54008 Boehringer Ingelheim Investigational Site", "city": "Capital Federal", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "205.456.54003 Boehringer Ingelheim Investigational Site", "city": "Florencio Varela", "country": "Argentina", "geoPoint": {"lat": -34.82722, "lon": -58.39556}}, {"facility": "205.456.54005 Boehringer Ingelheim Investigational Site", "city": "Mendoza", "country": "Argentina", "geoPoint": {"lat": -32.89084, "lon": -68.82717}}, {"facility": "205.456.54009 Boehringer Ingelheim Investigational Site", "city": "San Miguel de Tucuman", "country": "Argentina", "geoPoint": {"lat": -26.82414, "lon": -65.2226}}, {"facility": "205.456.54004 Boehringer Ingelheim Investigational Site", "city": "San Miguel de Tucum\u00e1n", "country": "Argentina", "geoPoint": {"lat": -26.82414, "lon": -65.2226}}, {"facility": "205.456.61002 Boehringer Ingelheim Investigational Site", "city": "Parkville", "state": "Victoria", "country": "Australia", "geoPoint": {"lat": -37.78333, "lon": 144.95}}, {"facility": "205.456.61001 Boehringer Ingelheim Investigational Site", "city": "Perth", "state": "Western Australia", "country": "Australia", "geoPoint": {"lat": -31.95224, "lon": 115.8614}}, {"facility": "205.456.35902 Boehringer Ingelheim Investigational Site", "city": "Plovdiv", "country": "Bulgaria", "geoPoint": {"lat": 42.15, "lon": 24.75}}, {"facility": "205.456.35901 Boehringer Ingelheim Investigational Site", "city": "Ruse", "country": "Bulgaria", "geoPoint": {"lat": 43.85639, "lon": 25.97083}}, {"facility": "205.456.35903 Boehringer Ingelheim Investigational Site", "city": "Sofia", "country": "Bulgaria", "geoPoint": {"lat": 42.69751, "lon": 23.32415}}, {"facility": "205.456.49008 Boehringer Ingelheim Investigational Site", "city": "Berlin", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "205.456.49001 Boehringer Ingelheim Investigational Site", "city": "Bochum", "country": "Germany", "geoPoint": {"lat": 51.48165, "lon": 7.21648}}, {"facility": "205.456.49004 Boehringer Ingelheim Investigational Site", "city": "Frankfurt", "country": "Germany", "geoPoint": {"lat": 50.11552, "lon": 8.68417}}, {"facility": "205.456.49005 Boehringer Ingelheim Investigational Site", "city": "Kehl", "country": "Germany", "geoPoint": {"lat": 48.57297, "lon": 7.81523}}, {"facility": "205.456.49003 Boehringer Ingelheim Investigational Site", "city": "Koblenz", "country": "Germany", "geoPoint": {"lat": 50.35357, "lon": 7.57883}}, {"facility": "205.456.49010 Boehringer Ingelheim Investigational Site", "city": "Mainz", "country": "Germany", "geoPoint": {"lat": 49.98419, "lon": 8.2791}}, {"facility": "205.456.49007 Boehringer Ingelheim Investigational Site", "city": "Neu-Isenburg", "country": "Germany", "geoPoint": {"lat": 50.04832, "lon": 8.69406}}, {"facility": "205.456.49002 Boehringer Ingelheim Investigational Site", "city": "Wesel", "country": "Germany", "geoPoint": {"lat": 51.6669, "lon": 6.62037}}, {"facility": "205.456.50201 Boehringer Ingelheim Investigational Site", "city": "Guatemala City", "country": "Guatemala", "geoPoint": {"lat": 14.64072, "lon": -90.51327}}, {"facility": "205.456.50203 Boehringer Ingelheim Investigational Site", "city": "Guatemala City", "country": "Guatemala", "geoPoint": {"lat": 14.64072, "lon": -90.51327}}, {"facility": "205.456.50204 Boehringer Ingelheim Investigational Site", "city": "Guatemala City", "country": "Guatemala", "geoPoint": {"lat": 14.64072, "lon": -90.51327}}, {"facility": "205.456.50205 Boehringer Ingelheim Investigational Site", "city": "Guatemala City", "country": "Guatemala", "geoPoint": {"lat": 14.64072, "lon": -90.51327}}, {"facility": "205.456.36005 Boehringer Ingelheim Investigational Site", "city": "Budapest", "country": "Hungary", "geoPoint": {"lat": 47.49801, "lon": 19.03991}}, {"facility": "205.456.36002 Boehringer Ingelheim Investigational Site", "city": "Debrecen", "country": "Hungary", "geoPoint": {"lat": 47.53333, "lon": 21.63333}}, {"facility": "205.456.36004 Boehringer Ingelheim Investigational Site", "city": "Gyula", "country": "Hungary", "geoPoint": {"lat": 46.65, "lon": 21.28333}}, {"facility": "205.456.36001 Boehringer Ingelheim Investigational Site", "city": "Miskolc", "country": "Hungary", "geoPoint": {"lat": 48.1, "lon": 20.78333}}, {"facility": "205.456.36007 Boehringer Ingelheim Investigational Site", "city": "Mosdos", "country": "Hungary", "geoPoint": {"lat": 46.35379, "lon": 17.98853}}, {"facility": "205.456.36006 Boehringer Ingelheim Investigational Site", "city": "Nagyatad", "country": "Hungary", "geoPoint": {"lat": 46.22961, "lon": 17.35788}}, {"facility": "205.456.97205 Boehringer Ingelheim Investigational Site", "city": "Holon", "country": "Israel", "geoPoint": {"lat": 32.01034, "lon": 34.77918}}, {"facility": "205.456.97203 Boehringer Ingelheim Investigational Site", "city": "Petach Tikva", "country": "Israel", "geoPoint": {"lat": 32.08707, "lon": 34.88747}}, {"facility": "205.456.97201 Boehringer Ingelheim Investigational Site", "city": "Safed", "country": "Israel", "geoPoint": {"lat": 32.96465, "lon": 35.496}}, {"facility": "205.456.37101 Boehringer Ingelheim Investigational Site", "city": "Baldone", "country": "Latvia", "geoPoint": {"lat": 56.74278, "lon": 24.39444}}, {"facility": "205.456.37104 Boehringer Ingelheim Investigational Site", "city": "Balvi", "country": "Latvia", "geoPoint": {"lat": 57.1313, "lon": 27.26583}}, {"facility": "205.456.37103 Boehringer Ingelheim Investigational Site", "city": "Rezekne", "country": "Latvia", "geoPoint": {"lat": 56.51025, "lon": 27.33994}}, {"facility": "205.456.37102 Boehringer Ingelheim Investigational Site", "city": "Riga", "country": "Latvia", "geoPoint": {"lat": 56.946, "lon": 24.10589}}, {"facility": "205.456.37105 Boehringer Ingelheim Investigational Site", "city": "Talsi", "country": "Latvia", "geoPoint": {"lat": 57.24562, "lon": 22.58137}}, {"facility": "205.456.52001 Boehringer Ingelheim Investigational Site", "city": "Hermosillo Sonora", "country": "Mexico"}, {"facility": "205.456.52002 Boehringer Ingelheim Investigational Site", "city": "Monterrey", "country": "Mexico", "geoPoint": {"lat": 25.67507, "lon": -100.31847}}, {"facility": "205.456.52003 Boehringer Ingelheim Investigational Site", "city": "Monterrey", "country": "Mexico", "geoPoint": {"lat": 25.67507, "lon": -100.31847}}, {"facility": "205.456.52004 Boehringer Ingelheim Investigational Site", "city": "Nuevo Le\u00f3n", "country": "Mexico"}, {"facility": "205.456.09001 Boehringer Ingelheim Investigational Site", "city": "Quezon City", "country": "Philippines", "geoPoint": {"lat": 14.6488, "lon": 121.0509}}, {"facility": "205.456.09002 Boehringer Ingelheim Investigational Site", "city": "Quezon City", "country": "Philippines", "geoPoint": {"lat": 14.6488, "lon": 121.0509}}, {"facility": "205.456.35105 Boehringer Ingelheim Investigational Site", "city": "Coimbra", "country": "Portugal", "geoPoint": {"lat": 40.20564, "lon": -8.41955}}, {"facility": "205.456.35101 Boehringer Ingelheim Investigational Site", "city": "Lisboa", "country": "Portugal", "geoPoint": {"lat": 38.71667, "lon": -9.13333}}, {"facility": "205.456.35102 Boehringer Ingelheim Investigational Site", "city": "Lisboa", "country": "Portugal", "geoPoint": {"lat": 38.71667, "lon": -9.13333}}, {"facility": "205.456.35104 Boehringer Ingelheim Investigational Site", "city": "Lisboa", "country": "Portugal", "geoPoint": {"lat": 38.71667, "lon": -9.13333}}, {"facility": "205.456.35103 Boehringer Ingelheim Investigational Site", "city": "Porto", "country": "Portugal", "geoPoint": {"lat": 41.14961, "lon": -8.61099}}, {"facility": "205.456.27001 Boehringer Ingelheim Investigational Site", "city": "Cape Town", "country": "South Africa", "geoPoint": {"lat": -33.92584, "lon": 18.42322}}, {"facility": "205.456.27002 Boehringer Ingelheim Investigational Site", "city": "Durban", "country": "South Africa", "geoPoint": {"lat": -29.8579, "lon": 31.0292}}, {"facility": "205.456.38006 Boehringer Ingelheim Investigational Site", "city": "Dnipropetrovsk", "country": "Ukraine", "geoPoint": {"lat": 48.4593, "lon": 35.03864}}, {"facility": "205.456.38004 Boehringer Ingelheim Investigational Site", "city": "Kharkiv", "country": "Ukraine", "geoPoint": {"lat": 49.98081, "lon": 36.25272}}, {"facility": "205.456.38003 Boehringer Ingelheim Investigational Site", "city": "Kiev", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"facility": "205.456.38010 Boehringer Ingelheim Investigational Site", "city": "Kriviy Rig", "country": "Ukraine"}, {"facility": "205.456.38009 Boehringer Ingelheim Investigational Site", "city": "Kyiv", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"facility": "205.456.38001 Boehringer Ingelheim Investigational Site", "city": "Lviv", "country": "Ukraine", "geoPoint": {"lat": 49.83826, "lon": 24.02324}}, {"facility": "205.456.38007 Boehringer Ingelheim Investigational Site", "city": "Lviv", "country": "Ukraine", "geoPoint": {"lat": 49.83826, "lon": 24.02324}}, {"facility": "205.456.38005 Boehringer Ingelheim Investigational Site", "city": "Uzhgorod", "country": "Ukraine", "geoPoint": {"lat": 48.61667, "lon": 22.3}}, {"facility": "205.456.38008 Boehringer Ingelheim Investigational Site", "city": "Vinnytsya", "country": "Ukraine", "geoPoint": {"lat": 49.23278, "lon": 28.48097}}, {"facility": "205.456.38002 Boehringer Ingelheim Investigational Site", "city": "Zaporizhzhya", "country": "Ukraine", "geoPoint": {"lat": 50.60727, "lon": 31.78792}}]}, "referencesModule": {"references": [{"pmid": "31319851", "type": "DERIVED", "citation": "Halpin DMG, Meltzer EO, Pisternick-Ruf W, Moroni-Zentgraf P, Engel M, Zaremba-Pechmann L, Casale T, FitzGerald JM. Peak expiratory flow as an endpoint for clinical trials in asthma: a comparison with FEV1. Respir Res. 2019 Jul 18;20(1):159. doi: 10.1186/s12931-019-1119-6."}, {"pmid": "27811070", "type": "DERIVED", "citation": "Hamelmann E, Bernstein JA, Vandewalker M, Moroni-Zentgraf P, Verri D, Unseld A, Engel M, Boner AL. A randomised controlled trial of tiotropium in adolescents with severe symptomatic asthma. Eur Respir J. 2017 Jan 11;49(1):1601100. doi: 10.1183/13993003.01100-2016. Print 2017 Jan."}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Placebo Respimat", "description": "Inhalation of placebo solution once daily for 12 weeks delivered by the Respimat Inhaler, as add on therapy on top of usual care."}, {"id": "FG001", "title": "Tio R2.5", "description": "Inhalation of 2.5mcg tiotropium bromide solution once daily for 12 weeks delivered by the Respimat Inhaler, as add on therapy on top of usual care."}, {"id": "FG002", "title": "Tio R5", "description": "Inhalation of 5mcg tiotropium bromide solution once daily for 12 weeks delivered by the Respimat Inhaler, as add on therapy on top of usual care."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "135"}, {"groupId": "FG001", "numSubjects": "127"}, {"groupId": "FG002", "numSubjects": "130"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "132"}, {"groupId": "FG001", "numSubjects": "126"}, {"groupId": "FG002", "numSubjects": "130"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Other Reason not Defined", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Treated set which included all randomised patients who were dispensed and received, at least one documented dose of trial medication.", "groups": [{"id": "BG000", "title": "Placebo Respimat", "description": "Inhalation of placebo solution once daily for 12 weeks delivered by the Respimat Inhaler, as add on therapy on top of usual care."}, {"id": "BG001", "title": "Tio R2.5", "description": "Inhalation of 2.5mcg tiotropium bromide solution once daily for 12 weeks delivered by the Respimat Inhaler, as add on therapy on top of usual care."}, {"id": "BG002", "title": "Tio R5", "description": "Inhalation of 5mcg tiotropium bromide solution once daily for 12 weeks delivered by the Respimat Inhaler, as add on therapy on top of usual care."}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "135"}, {"groupId": "BG001", "value": "127"}, {"groupId": "BG002", "value": "130"}, {"groupId": "BG003", "value": "392"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "14.1", "spread": "1.7"}, {"groupId": "BG001", "value": "14.4", "spread": "1.8"}, {"groupId": "BG002", "value": "14.3", "spread": "1.6"}, {"groupId": "BG003", "value": "14.2", "spread": "1.7"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "56"}, {"groupId": "BG001", "value": "47"}, {"groupId": "BG002", "value": "47"}, {"groupId": "BG003", "value": "150"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "79"}, {"groupId": "BG001", "value": "80"}, {"groupId": "BG002", "value": "83"}, {"groupId": "BG003", "value": "242"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "FEV1 peak0-3 Change From Baseline", "description": "Change from baseline in peak forced expiratory volume in 1 second within the first 3 hours post dosing (FEV1 peak0-3) measured at week 12.\n\nMeasured values presented are actually adjusted means.", "populationDescription": "Full Analysis Set (FAS) was the same as the treated set which included all randomised patients who were dispensed and received at least one documented dose of trial medication. Missing data at a visit was imputed by the available data from the patient at that visit. Completely missing data were handled by the statistical model.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "litres", "timeFrame": "Baseline and 12 weeks", "groups": [{"id": "OG000", "title": "Placebo Respimat", "description": "Inhalation of placebo solution once daily for 12 weeks delivered by the Respimat Inhaler, as add on therapy on top of usual care."}, {"id": "OG001", "title": "Tio R2.5", "description": "Inhalation of 2.5mcg tiotropium bromide solution once daily for 12 weeks delivered by the Respimat Inhaler, as add on therapy on top of usual care."}, {"id": "OG002", "title": "Tio R5", "description": "Inhalation of 5mcg tiotropium bromide solution once daily for 12 weeks delivered by the Respimat Inhaler, as add on therapy on top of usual care."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "132"}, {"groupId": "OG001", "value": "126"}, {"groupId": "OG002", "value": "130"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.438", "spread": "0.045"}, {"groupId": "OG001", "value": "0.550", "spread": "0.046"}, {"groupId": "OG002", "value": "0.528", "spread": "0.045"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0457", "pValueComment": "Stepwise testing of the null hypothesis was used to test the efficacy of Tio R5 and then Tio R2.5, each over placebo.", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "0.111", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.002", "ciUpperLimit": "0.220", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.055", "estimateComment": "Difference calculated as Tio R2.5 minus placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.1039", "pValueComment": "Stepwise testing of the null hypothesis was used to test the efficacy of Tio R5 and then Tio R2.5, each over placebo.", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "0.090", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.019", "ciUpperLimit": "0.198", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.055", "estimateComment": "Difference calculated as Tio R5 minus placebo"}]}, {"type": "SECONDARY", "title": "Trough FEV1 Change From Baseline", "description": "Change from baseline in Trough (pre-dose) Forced expiratory volume in 1 second (FEV1) measured at week 12.\n\nMeasured values presented are actually adjusted means.", "populationDescription": "Full Analysis Set (FAS) was the same as the treated set which included all randomised patients who were dispensed and received at least one documented dose of trial medication. Missing data at a visit was imputed by the available data from the patient at that visit. Completely missing data were handled by the statistical model.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "litres", "timeFrame": "Baseline and 12 weeks", "groups": [{"id": "OG000", "title": "Placebo Respimat", "description": "Inhalation of placebo solution once daily for 12 weeks delivered by the Respimat Inhaler, as add on therapy on top of usual care."}, {"id": "OG001", "title": "Tio R2.5", "description": "Inhalation of 2.5mcg tiotropium bromide solution once daily for 12 weeks delivered by the Respimat Inhaler, as add on therapy on top of usual care."}, {"id": "OG002", "title": "Tio R5", "description": "Inhalation of 5mcg tiotropium bromide solution once daily for 12 weeks delivered by the Respimat Inhaler, as add on therapy on top of usual care."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "132"}, {"groupId": "OG001", "value": "126"}, {"groupId": "OG002", "value": "130"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.230", "spread": "0.048"}, {"groupId": "OG001", "value": "0.345", "spread": "0.048"}, {"groupId": "OG002", "value": "0.284", "spread": "0.048"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0509", "pValueComment": "Stepwise testing of the null hypothesis was used to test the efficacy of Tio R5 and then Tio R2.5, each over placebo.", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "0.115", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.000", "ciUpperLimit": "0.231", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.059", "estimateComment": "Difference calculated as Tio R2.5 minus placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.3605", "pValueComment": "Stepwise testing of the null hypothesis was used to test the efficacy of Tio R5 and then Tio R2.5, each over placebo.", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "0.054", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.061", "ciUpperLimit": "0.168", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.058", "estimateComment": "Difference calculated as Tio R5 minus placebo"}]}, {"type": "SECONDARY", "title": "FVC peak0-3 Change From Baseline", "description": "Change from baseline in Maximum forced vital capacity (FVC) measured within the first 3 hours after administration of trial medication (FVC peak0-3h) after 12 weeks of treatment.\n\nThe measured values presented are actually adjusted means.", "populationDescription": "Full Analysis Set (FAS) was the same as the treated set which included all randomised patients who were dispensed and received at least one documented dose of trial medication. Missing data at a visit was imputed by the available data from the patient at that visit. Completely missing data were handled by the statistical model.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Litres", "timeFrame": "Baseline and 12 weeks", "groups": [{"id": "OG000", "title": "Placebo Respimat", "description": "Inhalation of placebo solution once daily for 12 weeks delivered by the Respimat Inhaler, as add on therapy on top of usual care."}, {"id": "OG001", "title": "Tio R2.5", "description": "Inhalation of 2.5mcg tiotropium bromide solution once daily for 12 weeks delivered by the Respimat Inhaler, as add on therapy on top of usual care."}, {"id": "OG002", "title": "Tio R5", "description": "Inhalation of 5mcg tiotropium bromide solution once daily for 12 weeks delivered by the Respimat Inhaler, as add on therapy on top of usual care."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "132"}, {"groupId": "OG001", "value": "126"}, {"groupId": "OG002", "value": "130"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.279", "spread": "0.048"}, {"groupId": "OG001", "value": "0.370", "spread": "0.049"}, {"groupId": "OG002", "value": "0.342", "spread": "0.048"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.1264", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "0.091", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.026", "ciUpperLimit": "0.207", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.059", "estimateComment": "Difference calculated as Tio R2.5 minus placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.2845", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "0.063", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.053", "ciUpperLimit": "0.179", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.059", "estimateComment": "Difference calculated as Tio R5 minus placebo"}]}, {"type": "SECONDARY", "title": "FEV1 AUC (0-3h) Change From Baseline", "description": "Change from baseline of area under the curve (AUC) from 0 to 3 hours for FEV1 (FEV1 AUC 0-3h) after 12 weeks of treatment. The AUC was calculated by using the trapezoidal rule divided by the observation time (3h).\n\nMeasured values presented are actually adjusted means.", "populationDescription": "Full Analysis Set (FAS) was the same as the treated set which included all randomised patients who were dispensed and received at least one documented dose of trial medication. Missing data at a visit was imputed by the available data from the patient at that visit. Completely missing data were handled by the statistical model.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Litres", "timeFrame": "Baseline and 10 mins before drug administration and 30 mins, 1 hour (h), 2h, 3h after drug administration at 12 weeks", "groups": [{"id": "OG000", "title": "Placebo Respimat", "description": "Inhalation of placebo solution once daily for 12 weeks delivered by the Respimat Inhaler, as add on therapy on top of usual care."}, {"id": "OG001", "title": "Tio R2.5", "description": "Inhalation of 2.5mcg tiotropium bromide solution once daily for 12 weeks delivered by the Respimat Inhaler, as add on therapy on top of usual care."}, {"id": "OG002", "title": "Tio R5", "description": "Inhalation of 5mcg tiotropium bromide solution once daily for 12 weeks delivered by the Respimat Inhaler, as add on therapy on top of usual care."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "132"}, {"groupId": "OG001", "value": "126"}, {"groupId": "OG002", "value": "130"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.336", "spread": "0.043"}, {"groupId": "OG001", "value": "0.449", "spread": "0.043"}, {"groupId": "OG002", "value": "0.423", "spread": "0.043"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0338", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "0.113", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.009", "ciUpperLimit": "0.217", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.053", "estimateComment": "Difference calculated as Tio R2.5 minus placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0999", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "0.087", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.017", "ciUpperLimit": "0.191", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.053", "estimateComment": "Difference calculated as Tio R5 minus placebo"}]}, {"type": "SECONDARY", "title": "FVC AUC (0-3h) Change From Baseline", "description": "Change from baseline of area under the curve (AUC) from 0 to 3 hours for FVC (Forced vital capacity) (FVC AUC0-3h) after 12 weeks of treatment. The AUC was calculated by using the trapezoidal rule divided by the observation time (3h).\n\nMeasured values presented are actually adjusted means.", "populationDescription": "Full Analysis Set (FAS) was the same as the treated set which included all randomised patients who were dispensed and received at least one documented dose of trial medication. Missing data at a visit was imputed by the available data from the patient at that visit. Completely missing data were handled by the statistical model.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "litres", "timeFrame": "Baseline and 10 mins before drug administration and 30 mins, 1 hour (h), 2h, 3h after drug administration at 12 weeks", "groups": [{"id": "OG000", "title": "Placebo Respimat", "description": "Inhalation of placebo solution once daily for 12 weeks delivered by the Respimat Inhaler, as add on therapy on top of usual care."}, {"id": "OG001", "title": "Tio R2.5", "description": "Inhalation of 2.5mcg tiotropium bromide solution once daily for 12 weeks delivered by the Respimat Inhaler, as add on therapy on top of usual care."}, {"id": "OG002", "title": "Tio R5", "description": "Inhalation of 5mcg tiotropium bromide solution once daily for 12 weeks delivered by the Respimat Inhaler, as add on therapy on top of usual care."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "132"}, {"groupId": "OG001", "value": "126"}, {"groupId": "OG002", "value": "130"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.175", "spread": "0.045"}, {"groupId": "OG001", "value": "0.262", "spread": "0.047"}, {"groupId": "OG002", "value": "0.227", "spread": "0.046"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.1252", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "0.087", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.024", "ciUpperLimit": "0.198", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.057", "estimateComment": "Difference calculated as Tio R2.5 minus placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.3549", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "0.052", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.058", "ciUpperLimit": "0.163", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.056", "estimateComment": "Difference calculated as Tio R5 minus placebo"}]}, {"type": "SECONDARY", "title": "Control of Asthma as Assessed by ACQ6 Score.", "description": "Change from baseline in Asthma Control Questionnaire (ACQ) 6 score measured at week 12\n\nThe ACQ is a scale containing 7 questions, each question has a 7 point scale which ranges from 0 to 6. A score of 0 corresponds to no impairment and a score of 6 corresponds to maximum impairment. ACQ6 score is calculated as the mean of the responses to the first 6 questions of the ACQ6.\n\nThe measured values presented are actually adjusted means.", "populationDescription": "Full Analysis Set (FAS) was the same as the treated set which included all randomised patients who were dispensed and received at least one documented dose of trial medication. Missing data at a visit was imputed by the available data from the patient at that visit. Completely missing data were handled by the statistical model.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline and 12 weeks", "groups": [{"id": "OG000", "title": "Placebo Respimat", "description": "Inhalation of placebo solution once daily for 12 weeks delivered by the Respimat Inhaler, as add on therapy on top of usual care."}, {"id": "OG001", "title": "Tio R2.5", "description": "Inhalation of 2.5mcg tiotropium bromide solution once daily for 12 weeks delivered by the Respimat Inhaler, as add on therapy on top of usual care."}, {"id": "OG002", "title": "Tio R5", "description": "Inhalation of 5mcg tiotropium bromide solution once daily for 12 weeks delivered by the Respimat Inhaler, as add on therapy on top of usual care."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "132"}, {"groupId": "OG001", "value": "126"}, {"groupId": "OG002", "value": "130"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.144", "spread": "0.069"}, {"groupId": "OG001", "value": "1.262", "spread": "0.071"}, {"groupId": "OG002", "value": "1.197", "spread": "0.070"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.1819", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "0.118", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.055", "ciUpperLimit": "0.292", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.088", "estimateComment": "Difference calculated as Tio R2.5 minus placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.5448", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "0.053", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.119", "ciUpperLimit": "0.226", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.088", "estimateComment": "Difference calculated as Tio R5 minus placebo"}]}, {"type": "SECONDARY", "title": "ACQ6 Score Responders", "description": "Responder rates based on the ACQ6 score after 12 weeks of treatment. Analysis was performed using the following categories and definitions: responder (change from trial baseline \\<= -0.5), no change (-0.5 \\< change from trial baseline \\<0.5) and worsening (change from trial baseline \\>= 0.5).\n\nThe ACQ is a scale containing 7 questions, each question has a 7- point scale which ranges from 0 to 6; a score of 0 corresponds to no impairment and a score of 6 corresponds to maximum impairment. ACQ6 is calculated as the mean of the responses to the first 6 questions of the ACQ6.\n\nNo statistical testing was performed on ACQ6 responders.", "populationDescription": "Full Analysis Set which included all randomised patients who were dispensed and received at least one documented dose of trial medication.\n\nMissing data for patients not withdrawn from the study were either categorised as no change or based on available data, withdrawn patients were imputed based upon discontinuation reason.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "12 weeks", "groups": [{"id": "OG000", "title": "Placebo Respimat", "description": "Inhalation of placebo solution once daily for 12 weeks delivered by the Respimat Inhaler, as add on therapy on top of usual care."}, {"id": "OG001", "title": "Tio R2.5", "description": "Inhalation of 2.5mcg tiotropium bromide solution once daily for 12 weeks delivered by the Respimat Inhaler, as add on therapy on top of usual care."}, {"id": "OG002", "title": "Tio R5", "description": "Inhalation of 5mcg tiotropium bromide solution once daily for 12 weeks delivered by the Respimat Inhaler, as add on therapy on top of usual care."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "135"}, {"groupId": "OG001", "value": "127"}, {"groupId": "OG002", "value": "130"}]}], "classes": [{"title": "Responder", "categories": [{"measurements": [{"groupId": "OG000", "value": "74.1"}, {"groupId": "OG001", "value": "74.0"}, {"groupId": "OG002", "value": "74.6"}]}]}, {"title": "No Change", "categories": [{"measurements": [{"groupId": "OG000", "value": "23.7"}, {"groupId": "OG001", "value": "19.7"}, {"groupId": "OG002", "value": "23.1"}]}]}, {"title": "Worsening", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.2"}, {"groupId": "OG001", "value": "6.3"}, {"groupId": "OG002", "value": "2.3"}]}]}]}, {"type": "SECONDARY", "title": "Control of Asthma as Assessed by ACQ Total Score", "description": "Change from baseline in Asthma Control Questionnaire (ACQ) total score measured at week 12.\n\nThe ACQ is a scale containing 7 questions. Each question has a 7 point scale which ranges from 0 to 6. A score of 0 corresponds to no impairment and a score of 6 corresponds to maximum impairment. ACQ total score is calculated as the mean of the responses to all 7 questions.\n\nThe measured values presented are actually adjusted means.", "populationDescription": "Full Analysis Set (FAS) was the same as the treated set which included all randomised patients who were dispensed and received at least one documented dose of trial medication. Missing data at a visit was imputed by the available data from the patient at that visit. Completely missing data were handled by the statistical model.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline and 12 weeks", "groups": [{"id": "OG000", "title": "Placebo Respimat", "description": "Inhalation of placebo solution once daily for 12 weeks delivered by the Respimat Inhaler, as add on therapy on top of usual care."}, {"id": "OG001", "title": "Tio R2.5", "description": "Inhalation of 2.5mcg tiotropium bromide solution once daily for 12 weeks delivered by the Respimat Inhaler, as add on therapy on top of usual care."}, {"id": "OG002", "title": "Tio R5", "description": "Inhalation of 5mcg tiotropium bromide solution once daily for 12 weeks delivered by the Respimat Inhaler, as add on therapy on top of usual care."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "132"}, {"groupId": "OG001", "value": "126"}, {"groupId": "OG002", "value": "130"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.234", "spread": "0.064"}, {"groupId": "OG001", "value": "1.292", "spread": "0.066"}, {"groupId": "OG002", "value": "1.270", "spread": "0.065"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.4762", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "0.058", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.102", "ciUpperLimit": "0.219", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.082", "estimateComment": "Difference calculated as Tio R2.5 minus placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.6558", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "0.036", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.123", "ciUpperLimit": "0.196", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.081", "estimateComment": "Difference calculated as Tio R5 minus placebo"}]}, {"type": "SECONDARY", "title": "ACQ Total Score Responders", "description": "Responder rates based on the ACQ total score after 12 weeks of treatment. Analysis was performed using the following categories and definitions: responder (change from trial baseline \u2264-0.5), no change (-0.5 \\<change from trial baseline \\<0.5) and worsening (change from trial baseline \u22650.5) No statistical testing was performed for ACQ total score responders.\n\nThe ACQ is a scale containing 7 questions, each question has a 7-point scale which ranges from 0 to 6; a score of 0 corresponds to no impairment and a score of 6 corresponds to maximum impairment.", "populationDescription": "Full Analysis Set which included all randomised patients who were dispensed and received at least one documented dose of trial medication. Missing data for patients not withdrawn from the study were either categorised as no change or based on available data. Withdrawn patients were imputed based upon discontinuation reason.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "12 weeks", "groups": [{"id": "OG000", "title": "Placebo Respimat", "description": "Inhalation of placebo solution once daily for 12 weeks delivered by the Respimat Inhaler, as add on therapy on top of usual care."}, {"id": "OG001", "title": "Tio R2.5", "description": "Inhalation of 2.5mcg tiotropium bromide solution once daily for 12 weeks delivered by the Respimat Inhaler, as add on therapy on top of usual care."}, {"id": "OG002", "title": "Tio R5", "description": "Inhalation of 5mcg tiotropium bromide solution once daily for 12 weeks delivered by the Respimat Inhaler, as add on therapy on top of usual care."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "135"}, {"groupId": "OG001", "value": "127"}, {"groupId": "OG002", "value": "130"}]}], "classes": [{"title": "Responder", "categories": [{"measurements": [{"groupId": "OG000", "value": "73.3"}, {"groupId": "OG001", "value": "74.8"}, {"groupId": "OG002", "value": "73.1"}]}]}, {"title": "No Change", "categories": [{"measurements": [{"groupId": "OG000", "value": "23.7"}, {"groupId": "OG001", "value": "22.0"}, {"groupId": "OG002", "value": "26.2"}]}]}, {"title": "Worsening", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.0"}, {"groupId": "OG001", "value": "3.1"}, {"groupId": "OG002", "value": "0.8"}]}]}]}, {"type": "SECONDARY", "title": "Use of PRN Rescue Medication During the Day", "description": "Change from baseline in the number of puffs of rescue medication (salbutamol/albuterol) used during the day (24 hour period) based on the weekly mean at week 12.\n\nThe measured values presented are actually adjusted means.", "populationDescription": "Full Analysis Set (FAS) was the same as the treated set which included all randomised patients who were dispensed and received at least one documented dose of trial medication. Missing data was imputed by the available data from the patient. Completely missing data were handled by the statistical model.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Number of puffs of rescue medication", "timeFrame": "Baseline and 12 weeks", "groups": [{"id": "OG000", "title": "Placebo Respimat", "description": "Inhalation of placebo solution once daily for 12 weeks delivered by the Respimat Inhaler, as add on therapy on top of usual care."}, {"id": "OG001", "title": "Tio R2.5", "description": "Inhalation of 2.5mcg tiotropium bromide solution once daily for 12 weeks delivered by the Respimat Inhaler, as add on therapy on top of usual care."}, {"id": "OG002", "title": "Tio R5", "description": "Inhalation of 5mcg tiotropium bromide solution once daily for 12 weeks delivered by the Respimat Inhaler, as add on therapy on top of usual care."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "131"}, {"groupId": "OG001", "value": "124"}, {"groupId": "OG002", "value": "130"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.482", "spread": "0.118"}, {"groupId": "OG001", "value": "-0.483", "spread": "0.122"}, {"groupId": "OG002", "value": "-0.540", "spread": "0.120"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.9960", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.001", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.301", "ciUpperLimit": "0.300", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.153"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.7030", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.058", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.355", "ciUpperLimit": "0.239", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.151"}]}, {"type": "SECONDARY", "title": "Use of PRN Rescue Medication During the Daytime", "description": "Change from baseline in the number of puffs of rescue medication (salbutamol/albuterol) used during the daytime based on the weekly mean at week 12.\n\nMeasured values presented are actually adjusted means.", "populationDescription": "Full Analysis Set (FAS) was the same as the treated set which included all randomised patients who were dispensed and received at least one documented dose of trial medication. Missing data was imputed by the available data from the patient. Completely missing data were handled by the statistical model.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Number of puffs of rescue medication", "timeFrame": "Baseline and 12 weeks", "groups": [{"id": "OG000", "title": "Placebo Respimat", "description": "Inhalation of placebo solution once daily for 12 weeks delivered by the Respimat Inhaler, as add on therapy on top of usual care."}, {"id": "OG001", "title": "Tio R2.5", "description": "Inhalation of 2.5mcg tiotropium bromide solution once daily for 12 weeks delivered by the Respimat Inhaler, as add on therapy on top of usual care."}, {"id": "OG002", "title": "Tio R5", "description": "Inhalation of 5mcg tiotropium bromide solution once daily for 12 weeks delivered by the Respimat Inhaler, as add on therapy on top of usual care."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "131"}, {"groupId": "OG001", "value": "124"}, {"groupId": "OG002", "value": "130"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.262", "spread": "0.073"}, {"groupId": "OG001", "value": "-0.295", "spread": "0.075"}, {"groupId": "OG002", "value": "-0.312", "spread": "0.073"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.7309", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.032", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.217", "ciUpperLimit": "0.153", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.094"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.5954", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.049", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.232", "ciUpperLimit": "0.133", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.093"}]}, {"type": "SECONDARY", "title": "Use of PRN Rescue Medication During the Night-time", "description": "Change from baseline in the number of puffs of rescue medication (salbutamol/albuterol) used during the night-time based on the weekly mean at week 12.\n\nMeasured values presented are actually adjusted means", "populationDescription": "Full Analysis Set (FAS) was the same as the treated set which included all randomised patients who were dispensed and received at least one documented dose of trial medication. Missing data was imputed by the available data from the patient. Completely missing data were handled by the statistical model.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Number of puffs of rescue medication", "timeFrame": "Baseline and 12 weeks", "groups": [{"id": "OG000", "title": "Placebo Respimat", "description": "Inhalation of placebo solution once daily for 12 weeks delivered by the Respimat Inhaler, as add on therapy on top of usual care."}, {"id": "OG001", "title": "Tio R2.5", "description": "Inhalation of 2.5mcg tiotropium bromide solution once daily for 12 weeks delivered by the Respimat Inhaler, as add on therapy on top of usual care."}, {"id": "OG002", "title": "Tio R5", "description": "Inhalation of 5mcg tiotropium bromide solution once daily for 12 weeks delivered by the Respimat Inhaler, as add on therapy on top of usual care."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "131"}, {"groupId": "OG001", "value": "124"}, {"groupId": "OG002", "value": "129"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.180", "spread": "0.064"}, {"groupId": "OG001", "value": "-0.092", "spread": "0.066"}, {"groupId": "OG002", "value": "-0.159", "spread": "0.065"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.2841", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "0.089", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.074", "ciUpperLimit": "0.252", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.083"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.7950", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "0.021", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.140", "ciUpperLimit": "0.182", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.082"}]}, {"type": "SECONDARY", "title": "Time to First Severe Asthma Exacerbation During the 12-week Treatment Period.", "description": "Time in days to first severe asthma exacerbation during the 12 week treatment period. The median time to first severe asthma exacerbation was not calculable, so the number of patients who experienced a severe asthma exacerbation are presented for the measured values.\n\nA severe asthma exacerbation was defined as a subgroup of all asthma exacerbations that required an initiation of treatment with systemic corticosteroids for at least 3 days or, in case of ongoing and pre-existing systemic corticosteroid therapy, requiring at least doubling of previous daily doses of systemic corticosteroids for at least 3 days.", "populationDescription": "Full Analysis Set (FAS) was the same as the treated set which included all randomised patients who were dispensed and received at least one documented dose of trial medication.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "12 weeks", "groups": [{"id": "OG000", "title": "Placebo Respimat", "description": "Inhalation of placebo solution once daily for 12 weeks delivered by the Respimat Inhaler, as add on therapy on top of usual care."}, {"id": "OG001", "title": "Tio R2.5", "description": "Inhalation of 2.5mcg tiotropium bromide solution once daily for 12 weeks delivered by the Respimat Inhaler, as add on therapy on top of usual care."}, {"id": "OG002", "title": "Tio R5", "description": "Inhalation of 5mcg tiotropium bromide solution once daily for 12 weeks delivered by the Respimat Inhaler, as add on therapy on top of usual care."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "135"}, {"groupId": "OG001", "value": "127"}, {"groupId": "OG002", "value": "130"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "2"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.9671", "statisticalMethod": "Regression, Cox", "paramType": "Hazard Ratio (HR)", "paramValue": "1.06", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.07", "ciUpperLimit": "16.95"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.5557", "statisticalMethod": "Regression, Cox", "paramType": "Hazard Ratio (HR)", "paramValue": "2.06", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.19", "ciUpperLimit": "22.70"}]}, {"type": "SECONDARY", "title": "Analysis of Time to First Asthma Exacerbation During the 12 Week Treatment Period.", "description": "Time in days to first asthma exacerbation during the 12 week treatment period. The median time to first asthma exacerbation was not calculable, so the number of patients who experienced an asthma exacerbation are presented for the measured values.", "populationDescription": "Full Analysis Set (FAS) was the same as the treated set which included all randomised patients who were dispensed and received at least one documented dose of trial medication.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "12 weeks", "groups": [{"id": "OG000", "title": "Placebo Respimat", "description": "Inhalation of placebo solution once daily for 12 weeks delivered by the Respimat Inhaler, as add on therapy on top of usual care."}, {"id": "OG001", "title": "Tio R2.5", "description": "Inhalation of 2.5mcg tiotropium bromide solution once daily for 12 weeks delivered by the Respimat Inhaler, as add on therapy on top of usual care."}, {"id": "OG002", "title": "Tio R5", "description": "Inhalation of 5mcg tiotropium bromide solution once daily for 12 weeks delivered by the Respimat Inhaler, as add on therapy on top of usual care."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "135"}, {"groupId": "OG001", "value": "127"}, {"groupId": "OG002", "value": "130"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "25"}, {"groupId": "OG001", "value": "18"}, {"groupId": "OG002", "value": "15"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.3567", "statisticalMethod": "Regression, Cox", "paramType": "Hazard Ratio (HR)", "paramValue": "0.75", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.41", "ciUpperLimit": "1.38"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.1168", "statisticalMethod": "Regression, Cox", "paramType": "Hazard Ratio (HR)", "paramValue": "0.60", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.32", "ciUpperLimit": "1.14"}]}, {"type": "SECONDARY", "title": "Clinically Relevant Abnormalities for Physical Examination, ECG, Vital Signs and Laboratory Tests", "description": "Clinically relevant abnormalities for physical examination, ECG, vital signs and laboratory tests. New abnormal findings or worsening of baseline conditions were reported as adverse events.", "populationDescription": "Treated set which included all randomised patients who were dispensed and received, at least one documented dose of trial medication.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "From first drug administration until 30 days after last drug intake, up to 142 days", "groups": [{"id": "OG000", "title": "Placebo Respimat", "description": "Inhalation of placebo solution once daily for 12 weeks delivered by the Respimat Inhaler, as add on therapy on top of usual care."}, {"id": "OG001", "title": "Tio R2.5", "description": "Inhalation of 2.5mcg tiotropium bromide solution once daily for 12 weeks delivered by the Respimat Inhaler, as add on therapy on top of usual care."}, {"id": "OG002", "title": "Tio R5", "description": "Inhalation of 5mcg tiotropium bromide solution once daily for 12 weeks delivered by the Respimat Inhaler, as add on therapy on top of usual care."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "135"}, {"groupId": "OG001", "value": "127"}, {"groupId": "OG002", "value": "130"}]}], "classes": [{"title": "Peak expiratory flow rate decreased", "categories": [{"measurements": [{"groupId": "OG000", "value": "9.6"}, {"groupId": "OG001", "value": "7.1"}, {"groupId": "OG002", "value": "3.8"}]}]}, {"title": "Blood glucose decreased", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.0"}, {"groupId": "OG001", "value": "0.8"}, {"groupId": "OG002", "value": "0.0"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "From first drug administration until 30 days after last drug intake, up to 142 days", "description": "Treated set which included all randomised patients who were dispensed and received at least one documented dose of trial medication.", "eventGroups": [{"id": "EG000", "title": "Placebo Respimat", "description": "Inhalation of placebo solution once daily for 12 weeks delivered by the Respimat Inhaler, as add on therapy on top of usual care.", "seriousNumAffected": 0, "seriousNumAtRisk": 135, "otherNumAffected": 23, "otherNumAtRisk": 135}, {"id": "EG001", "title": "Tio R2.5", "description": "Inhalation of 2.5mcg tiotropium bromide solution once daily for 12 weeks delivered by the Respimat Inhaler, as add on therapy on top of usual care.", "seriousNumAffected": 1, "seriousNumAtRisk": 127, "otherNumAffected": 23, "otherNumAtRisk": 127}, {"id": "EG002", "title": "Tio R5", "description": "Inhalation of 5mcg tiotropium bromide solution once daily for 12 weeks delivered by the Respimat Inhaler, as add on therapy on top of usual care.", "seriousNumAffected": 2, "seriousNumAtRisk": 130, "otherNumAffected": 16, "otherNumAtRisk": 130}], "seriousEvents": [{"term": "Pyoderma", "organSystem": "Infections and infestations", "sourceVocabulary": "MEDDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 135}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 127}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 130}]}, {"term": "Ligament sprain", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MEDDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 135}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 127}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 130}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MEDDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 135}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 127}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 130}]}, {"term": "Dermatitis atopic", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MEDDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 135}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 127}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 130}]}], "otherEvents": [{"term": "Peak expiratory flow rate decreased", "organSystem": "Investigations", "sourceVocabulary": "MEDDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 13, "numAtRisk": 135}, {"groupId": "EG001", "numAffected": 9, "numAtRisk": 127}, {"groupId": "EG002", "numAffected": 5, "numAtRisk": 130}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MEDDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 14, "numAtRisk": 135}, {"groupId": "EG001", "numAffected": 14, "numAtRisk": 127}, {"groupId": "EG002", "numAffected": 14, "numAtRisk": 130}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BIs intellectual property rights."}, "pointOfContact": {"title": "Boehringer Ingelheim Call Center", "organization": "Boehringer Ingelheim Pharmaceuticals", "email": "clintriage.rdg@boehringer-ingelheim.com", "phone": "1-800-243-0127"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["Italy", "Norway"]}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M27137", "name": "Respiratory Aspiration", "relevance": "LOW"}, {"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC20", "name": "Immune System Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000069447", "term": "Tiotropium Bromide"}], "ancestors": [{"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000010276", "term": "Parasympatholytics"}, {"id": "D000018680", "term": "Cholinergic Antagonists"}, {"id": "D000018678", "term": "Cholinergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M21860", "name": "Pharmaceutical Solutions", "relevance": "LOW"}, {"id": "M416", "name": "Tiotropium Bromide", "asFound": "Melanoma", "relevance": "HIGH"}, {"id": "M5241", "name": "Bromides", "relevance": "LOW"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M13189", "name": "Parasympatholytics", "relevance": "LOW"}, {"id": "M20760", "name": "Cholinergic Antagonists", "relevance": "LOW"}, {"id": "M20758", "name": "Cholinergic Agents", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "PhSol", "name": "Pharmaceutical Solutions"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "AntiConv", "name": "Anticonvulsants"}]}}, "hasResults": true}